Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
Executive Summary
J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection
You may also be interested in...
Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa
Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22
Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa
Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22
Invega Review Shows FDAers At Odds On Safety Issues
FDA review documents illustrate internal disagreement at the division level during the agency's review of Johnson & Johnson's schizophrenia agent Invega. The review also highlights the difficulty in assessing safety in the unique patient population affected by schizophrenia